As expected, Gilead Sciences has earned the FDA's approval for Cayston, a new drug that will be used to treat lung infections in patients with cystic fibrosis.
Cayston won a lopsided FDA panel vote last December and Bloomberg says that analysts who follow the company expect it will earn around $161.7 million by 2014. As the news service also notes, that's a relatively small amount when you compare it to the mega blockbuster revenue Gilead will be looking for from its late-stage combo HIV therapy.
"All of us at Gilead extend our thanks to the investigators and to the people with cystic fibrosis who took part in the Cayston clinical trials," said Norbert Bischofberger, Gilead's executive vice president, research and development, in the company's statement. "We look forward to making Cayston available to the cystic fibrosis community as soon as possible."
- here's Gilead's release
- check out the Bloomberg story